Cost objections mask deeper anxieties about credibility, safety, and outcome certainty. Learn to listen, respond, and build the trust that drives case acceptance—especially in complex protocols like MARPE and skeletal expansion.
TL;DR When a patient asks 'What does it cost?' they are often signaling deeper concerns about trust, provider credibility, and treatment value. Orthodontists who reframe cost objections as trust-building opportunities—by transparently discussing skeletal expansion benefits, treatment timelines, and evidence—achieve higher case acceptance and stronger doctor-patient relationships.
The opening consultation question 'What does it cost?' rarely reflects the patient's true concern. In this article, Dr. Mark Radzhabov explores the psychology behind orthodontic patient communication—specifically, how to recognize the trust-building opportunity embedded in financial objections. Whether you're planning a MARPE protocol, discussing MSE rapid palatal expansion, or presenting conventional treatment, understanding what patients really want to hear will transform your case presentation and case acceptance rates.
When a patient asks about price in the initial consultation, they have already moved past the primary decision gate: 'Do I need treatment?' The cost question is rarely, in isolation, the actual barrier. Instead, it serves as a proxy for several unspoken anxieties: Am I being exploited? Will this provider deliver what they promise? Is the outcome worth the investment? Can I trust this person with my or my child's care?
Clinical observation from practices that track case acceptance shows that patients who receive a detailed explanation of clinical findings—CBCT imaging data, midpalatal suture status, skeletal maturity markers—before hearing the fee quote, exhibit higher trust and lower price sensitivity. The reversal is instructive: when cost is presented first, patients mentally anchor to the fee and evaluate everything thereafter through a cost-justification lens. When clinical credibility precedes financial discussion, patients evaluate cost through a value lens.
In the orthodontist patient communication literature, this phenomenon aligns with what psychologists call 'sequential anchoring.' The first substantive information a patient receives—whether clinical or financial—becomes the frame for all downstream reasoning. If you lead with evidence (imaging, diagnosis, evidence-based protocol), the patient's brain is primed to ask, 'How much is it worth?' If you lead with cost, the brain asks, 'Is this worth it?'
The patient asking 'What does it cost?' is often implicitly asking: 'Is this person professional enough, knowledgeable enough, and ethical enough to deserve my investment?' Your answer—and more importantly, your *approach* to answering—either confirms or undermines their emerging trust.
Layer 1: Clinical Diagnosis & Imaging. Begin the consultation by walking the patient through CBCT findings, cephalometric analysis, and functional assessment. Show the lateral cephalogram, point out the maxillary deficiency, explain skeletal vs. dentoalveolar contributions to the malocclusion. When discussing potential MARPE protocol or other skeletal expansion options, reference the specific anatomical rationale: 'Your child's midpalatal suture is still malleable, which means we can harness the body's own biology to expand the upper jaw.' This language shifts the frame from 'I want to sell you an expensive appliance' to 'Here's why your anatomy is a candidate for this particular approach.'
Layer 2: Evidence-Based Protocol & Timeline. After diagnosis, present the treatment plan with reference to current best practices. Explain why you have chosen a particular modality—whether conventional RPE, MARPE, or staged treatment. For MARPE treatment planning specifically, discuss the biomechanical advantage: miniscrew-assisted expansion distributes force more directly to the palatal suture and reduces unwanted buccal tooth tipping compared to conventional rapid palatal expansion devices. Describe the timeline: active phase duration, retention period, expected skeletal response. Patients accept higher fees when they understand *why* duration matters and *what* happens at each stage.
Layer 3: Financial Investment & ROI. Only after establishing clinical credibility and explaining the protocol should you discuss fee. Frame cost within the context of the comprehensive plan: 'Given the skeletal deficiency and the fact that your son is in the optimal window for growth modification, a MARPE protocol will cost X dollars and take Y months. Without intervention, you'd be looking at more invasive surgical options later, or lifelong compensation.' The patient has now heard diagnosis, evidence, and timeline—all of which justify investment. Cost becomes the final, logical piece of information, not the first.
The moment a patient voices a cost concern—whether directly ('That's more than I expected') or indirectly ('Let me think about it' after hearing the fee)—you have a critical 30-second window. Your response determines whether the patient perceives you as dismissive of their concern or as a trusted advisor who takes their hesitation seriously.
Do not defend the price. Defensive language ('This is the standard fee in our region' or 'Other orthodontists charge more') signals that you see the patient's hesitation as a threat, not a legitimate question. Instead, re-engage with the clinical rationale. Example: 'I hear you. Let me walk back through why we're recommending this specific approach. The MARPE protocol costs more upfront than a conventional expander would, because the miniscrew system requires surgical placement and precision engineering. But the trade-off is that you avoid the tooth tipping and skeletal compensation that often happens with tooth-borne expansion. Over a 24-month treatment window, that's an investment in skeletal correction that your child would otherwise need surgical intervention to achieve as an adult. Does that clinical distinction make sense?'
This response does three things simultaneously: (1) validates the patient's concern, (2) restates the clinical advantage of the recommended approach, and (3) contextualizes cost within long-term health benefit rather than short-term expense. The patient feels heard, informed, and positioned as a collaborator in the decision.
If the patient still hesitates, offer transparent alternatives: 'If the miniscrew-assisted approach feels out of reach right now, we could discuss a phased plan. We could start with conventional RPE in the near term and potentially upgrade to skeletal retention later. I want to be honest: RPE alone will move teeth more than bone, but it's a valid starting point if timing or budget matters. What feels right for your family?'
Patients and parents are increasingly informed by online research before the consultation. They've often read marketing claims about MARPE, MSE, and rapid palatal expansion. Your role is to provide honest, evidence-based context that differentiates legitimate efficacy from marketing overreach.
A prospective randomized clinical trial comparing conventional RPE and miniscrew-assisted RPE (Chun et al., 2022, BMC Oral Health) found that both methods achieved midpalatal suture separation in >90% of adolescent and young adult patients when identical expansion (35 turns) was delivered. The key clinical difference: MARPE produced greater nasal width increases in the molar region and greater skeletal width gains at the palatal foramen compared to tooth-borne RPE. Critically, MARPE produced less buccal displacement (tipping) of the anchor teeth. This means the skeletal gain was preserved as actual jaw width, not lost to dental compensation. When explaining this to a patient, say: 'The research shows that miniscrew-assisted expansion delivers bone width gains more efficiently—less of the expansion is wasted on tooth movement and more goes to actual jaw growth.'
For adult patients with fused sutures, the clinical situation is different. Surgical RPE (SARPE) remains the gold standard for fully skeletally mature patients requiring large transverse expansion, though it is significantly more invasive and costly than MARPE or conventional RPE. MARPE in non-growing adults is emerging as a viable intermediate option in specific cases, though success is less predictable and depends heavily on residual suture compliance. Be honest about age-dependent efficacy: 'Your daughter is 16, which is still in a window where we have a very good chance of skeletal response with miniscrew-assisted expansion. If she were 25, we'd need to have a different conversation about whether the suture is still responsive, and surgery might be a consideration. Her age is actually in our favor here.'
One of the most effective trust-building moves in skeletal expansion consultation is to explicitly discuss the retention phase and why it matters. Patients often underestimate the role of post-expansion consolidation in preventing relapse. A clinical protocol based on Russian patent literature and international best practice describes 6-month retention periods after active expansion, followed by dynamic patient follow-up. When you explain this during consultation, you are signaling that your fee includes not just the 'active' treatment phase but long-term monitoring and stability.
Frame retention as a shared responsibility: 'After we finish the active expansion phase—roughly 8 to 10 weeks—we move into a 6-month retention period where I'm monitoring the suture and the bone is consolidating around the new width. This is when your compliance matters. If we're using a bonded retainer, you'll need to maintain excellent oral hygiene. If we're using a removable retainer, you'll wear it as directed. This period is when we lock in the skeletal gain we've worked for. It's why I recommend retention as part of the treatment fee, not an add-on surprise.' This transparency converts a potential cost objection ('Why am I paying for retainers?') into understood necessity.
Additionally, discuss what happens if the patient does not comply with retention. 'If the retainer isn't worn consistently, bone and teeth can drift back to some degree. This doesn't mean the entire treatment is lost, but it means we're working against biology. I want to be upfront so you can decide whether your family is ready for this commitment.' Patients respect clinicians who set realistic expectations and acknowledge their own role in outcomes.
Fundamental course covering CBCT patient selection, miniscrew planning, activation protocols, and 60+ clinical cases. Choose the access level that fits your practice.
Essentials of rapid palatal expansion for practicing orthodontists.
Deep-dive into MARPE protocol, diagnostics, and clinical execution.
5-element medical consultation framework for dentists and orthodontists.
Acknowledge the cost difference, then reframe: 'MARPE costs more because the miniscrew system is surgical, but you avoid tooth tipping and dental compensation. You're paying for skeletal correction, not just tooth movement. Conventional RPE is valid if budget is the constraint, but I want you to understand the clinical trade-off.'
MARPE success is highest in adolescents and young adults (14–25 years). In fully mature adults (30+), suture fusion limits skeletal response significantly. Age 14–20 offers the best prognosis; discuss surgical options (SARPE) for older patients with large transverse deficiency.
Six-month retention allows bone consolidation around new palatal width. Without adequate retention, dental and skeletal relapse can occur. Tell patients: 'Retention isn't optional—it's when we lock in the skeletal gain. Your compliance during this phase directly affects long-term stability.'
Reference prospective data: miniscrew-assisted expansion achieves >90% midpalatal suture separation in adolescents, with greater skeletal width and less tooth tipping than conventional RPE. But acknowledge: success depends on miniscrew stability, suture responsiveness, and retention compliance.
Discuss CBCT findings, skeletal vs. dentoalveolar contributions to malocclusion, and midpalatal suture status. Specific anatomical language ('Your maxilla is 4 mm narrow at the molar level') signals expertise and differentiates you from generic consultants.
Not as a first strategy. Instead, strengthen the clinical justification for the fee. If budget is genuinely limiting, transparently offer phased treatment or conventional alternatives. Discounting early undermines perceived value and credibility.
Listen for follow-up questions. True budget concerns are followed by 'Can we do a payment plan?' Trust concerns are followed by silence or vague pushback. Address trust first with additional clinical detail; address budget second with transparent options.
Be matter-of-fact: 'Without retention, some relapse occurs—this is biology, not failure. With retention, we minimize relapse to acceptable levels. Your compliance during retention is the single biggest predictor of long-term stability.'
Show the CBCT during consultation. Point out suture morphology, assess remaining growth potential, measure transverse deficiency. Say: 'The imaging confirms that miniscrew-assisted expansion is biomechanically ideal for your anatomy. The precision placement these images allow justifies the cost.'
No. Focus on your clinical approach and evidence base. Say: 'I can only speak to my protocol and outcomes. I invest in training, imaging technology, and precision systems because I believe they deliver better results. You can compare clinicians on experience and approach, not just price.'
Patients invest in orthodontists they trust, not just in treatment. By listening carefully to the real question behind 'What does it cost?'—and responding with transparent, evidence-based explanation of your clinical approach—you create the foundation for long-term compliance and referral relationships. Dr. Mark Radzhabov and the Orthodontist Mark community emphasize that skilled orthodontist patient communication is itself a clinical skill worth developing deliberately. Schedule a case review or explore our consultation protocol course to refine your own communication framework.